Attached files
| file | filename |
|---|---|
| EX-99 - INVESTOR SLIDES UBS CONFERENCE - WEST PHARMACEUTICAL SERVICES INC | slides.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported) – September 22, 2010
________________________
WEST PHARMACEUTICAL SERVICES, INC.
(Exact name of registrant as specified in its charter)
_____________________
|
Pennsylvania
|
1-8036
|
23-1210010
|
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
101 Gordon Drive, PO Box 645, Lionville, PA
|
19341-0645
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
610-594-2900
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or address, if changed since last report)
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure
On September 9, 2010, West Pharmaceutical Services, Inc. announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William J. Federici, Chief Financial Officer, will present at the UBS 2010 Global Life Sciences Conference in New York, NY on September 22, 2010 at 11:30 AM ET.
A copy of the presentation materials they will use at the conference is attached to this Report as Exhibit 99 and is incorporated herein by reference. The materials will also be available for 30 days through the Investors link at the Company’s website, http://www.westpharma.com.
The information in this report is being furnished under Item 7.01, Regulation FD Disclosure, and is not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor is it deemed to be incorporated by reference in any filing under that Act or the Securities Act of 1933.
Item 9.01 Financials Statement and Exhibits
|
(d)
|
Exhibits
|
|
|
99
|
West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation Materials).
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
WEST PHARMACEUTICAL SERVICES, INC.
|
|
/s/ John R. Gailey III
|
|
John R. Gailey III
|
|
Vice President, General Counsel and Secretary
|
September 22, 2010
3
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
99
|
West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation Materials).
|
4